Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://www.journalmc.org

Case Report

Volume 12, Number 1, January 2021, pages 37-40

Resolution of Chronic Immune Thrombocytopenia Purpura after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma

Figures

Figure 1.
Figure 1. The trends of platelets, hemoglobin and white blood cells over time. (a) Patient received his last platelet transfusion 42 days post HSCT and last romiplostim treatment 75 days post HSCT. His ITP has been in complete remission for 498 days as per electronic medical records and is continuing in remission at current time. (b) Trend of hemoglobin over time in relation to HSCT and last platelet transfusion. (c) Trend of white blood cell count in relation to HSCT. HSCT: hematopoietic stem cell transplant; ITP: immune thrombocytopenic purpura.
Figure 2.
Figure 2. PET/CT monitoring shows that patient’s DLBCL is still in remission 1 year after autologous HSCT. (a) PET/CT before HSCT. Inferior right hilar lymph node with SUV max of 5.5 (arrow). (b) PET/CT 1 year after HSCT. Continued decline in the metabolic activity within the inferior right hilar lymph node with SUV max of 3.9. No new metabolic activity was observed in whole body. PET/CT: positron emission tomography/computed tomography; DLBCL: diffuse large B-cell lymphoma; HSCT: hematopoietic stem cell transplant; SUV: standardized uptake value.